

MULTIPLE MYELOMA *by the Numbers*

Multiple myeloma is an incurable and rare cancer that starts in plasma cells in the bone marrow¹

 Nearly **230,000** people
AROUND THE WORLD ARE LIVING WITH THIS DISEASE²

2ND MOST COMMON
BLOOD CANCER³



WITH **~124,000** NEW CASES DIAGNOSED EACH IN 2015 AND **87,000** DEATHS IN 2015^{4,5}


 **1.5X** INCIDENCE AMONG MEN⁶

MEDIAN AGE AT DIAGNOSIS⁷

70

AFTER INITIAL DIAGNOSIS, THE **5-YEAR SURVIVAL RATE IS⁸**

44%



Coping with multiple myeloma can be a difficult journey and affects the whole family⁹

Most patients will eventually experience a **RELAPSE** of the disease & some patients also become **REFRACTORY**¹⁰

? **REFRACTORY** occurs when the disease is unresponsive to a primary therapy or becomes unresponsive over time¹⁰

? **RELAPSE** occurs when the disease and/or the signs and symptoms of a disease return after a period of improvement¹¹

APPROXIMATELY **75,000 PATIENTS**



AROUND THE WORLD
ARE LIVING WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA¹²

References

1. American Cancer Society. Multiple Myeloma. Accessed at <http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-it>. Accessed November 2015.
2. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence in 2015. Available at http://globocan.iarc.fr/old/summary_table_site_prev.asp?selection=17270&title=Multiple+myeloma&sex=0&africa=1&america=2&asia=3&europe=4&oceania=5&build=6&>window=1&sort=0&submit=%C2%A0Execute Accessed November 2015.
3. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging Therapies for the Treatment of Relapsed or Refractory Multiple Myeloma. Eur. J. Hematology. 2011; 86(1): 1-15.
4. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence in 2015. Available at http://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Textp=World&selection_cancer=17270&Text-c=Multiple+myeloma&pYear=3&type=0&window=1&submit=%C2%A0Execute Accessed November 2015.
5. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence in 2015. Available at http://globocan.iarc.fr/old/burden.asp?selection_pop=224900&Textp=World&selection_cancer=17270&Text-c=Multiple+myeloma&pYear=3&type=1&window=1&submit=%C2%A0Execute Accessed November 2015.
6. Landgren, O, et al. Familial Characteristics of Autoimmune and Hematologic Disorders in 8,406 Multiple Myeloma Patients: A Population-Based Case-Control Study. In. J. Cancer. 2006; 118: 3095-3098.
7. Nau K and Lewis W. Multiple Myeloma: Diagnosis and Treatment. American Family Physician. 2008; 78(7):853-859.
8. Pulte D, et al. Recent Improvement in Survival of Patients with Multiple Myeloma: Variation by Ethnicity. Leuk Lymphoma. 2014; 55(5):1083-9.
9. Kurtin, S, et al. Caregivers of Multiple Myeloma Survivors. Clinical Journal of Oncology Nursing. 2013; 17(6): 25-32.
10. The Leukemia and Lymphoma Society. Myeloma. Revised 2013; 1:48.
11. National Cancer Institute. NCI Dictionary of Cancer Terms. Relapse. Available at <http://www.cancer.gov/publications/dictionaries/cancer-terms/CdrID=45866> Accessed November 2015.
12. Novartis data on file